Glycozar 40mg Tablet contains Gliclazide, a sulfonylurea class oral hypoglycemic agent used in the management of type 2 diabetes mellitus. It functions by stimulating pancreatic beta cells to release insulin, thereby improving glycemic control in patients with non-insulin-dependent diabetes. Glycozar is indicated as an adjunct to diet and exercise to improve blood glucose levels when these measures alone are insufficient. The 40mg dosage allows for flexible titration based on individual patient response and glycemic targets. Gliclazide has a relatively low risk of hypoglycemia compared to other sulfonylureas and may also exhibit antioxidant properties that contribute to vascular protection. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and hypersensitivity to sulfonylureas. Common adverse effects include hypoglycemia, gastrointestinal disturbances, and allergic skin reactions. Regular monitoring of blood glucose and periodic assessment of renal and hepatic function are recommended during therapy. Dose adjustments may be necessary in elderly patients or those with compromised organ function. Glycozar should be used cautiously with other medications that affect blood sugar levels to avoid hypoglycemic episodes. Patient education on adherence, diet, and recognition of hypoglycemia symptoms is essential for optimal therapeutic outcomes.